Search

Your search keyword '"Yasuda, Ichiro"' showing total 1,652 results
Start Over Author "Yasuda, Ichiro"
1,652 results on '"Yasuda, Ichiro"'

51. Postprocedure serum amylase or lipase levels predict postendoscopic retrograde cholangiopancreatography pancreatitis: Meta‐analysis of diagnostic test accuracy studies and utility assessment

Author

Hirota, Morihisa, primary, Itoi, Takao, additional, Morizane, Toshio, additional, Koiwai, Akinobu, additional, Yasuda, Ichiro, additional, Ryozawa, Shomei, additional, Mukai, Shuntaro, additional, Ikeura, Tsukasa, additional, Irisawa, Atsushi, additional, Iwasaki, Eisuke, additional, Katanuma, Akio, additional, Kitamura, Katsuya, additional, Takenaka, Mamoru, additional, Ito, Tetsuhide, additional, Masamune, Atsushi, additional, Mayumi, Toshihiko, additional, and Takeyama, Yoshifumi, additional

Published
2023
Full Text
View/download PDF

52. Risk of recurrence with or without plastic stent after EUS-guided treatment of peripancreatic fluid collections: A systematic review and meta-analysis

Author

Iwashita, Takuji, primary, Sato, Tatsuya, primary, Yasuda, Ichiro, primary, Nakai, Yousuke, primary, Hamada, Tsuyoshi, additional, Saito, Tomotaka, additional, Iwata, Keisuke, additional, Shiomi, Hideyuki, additional, Takenaka, Mamoru, additional, Maruta, Akinori, additional, Uemura, Shinya, additional, Masuda, Atsuhiro, additional, Matsubara, Saburo, additional, Mukai, Tsuyoshi, additional, and Isayama, Hiroyuki, additional

Published
2023
Full Text
View/download PDF

61. Peroral Pancreatoscopy-Guided Lithotripsy Compared with Extracorporeal Shock Wave Lithotripsy in the Management of Pancreatic Duct Stones in Chronic Pancreatitis: A Multicenter Retrospective Cohort Study.

Author

Iwata, Keisuke, Iwashita, Takuji, Mukai, Tsuyoshi, Iwasa, Yuhei, Okuno, Mitsuru, Yoshida, Kensaku, Maruta, Akinori, Uemura, Shinya, Yasuda, Ichiro, and Shimizu, Masahito

Subjects
EXTRACORPOREAL shock wave lithotripsy, PANCREATIC duct, CHRONIC pancreatitis, COHORT analysis
Abstract

Background: Extracorporeal shock wave lithotripsy (ESWL) is a common treatment for pancreatic stones in chronic pancreatitis. In contrast, peroral pancreatoscopy-guided lithotripsy (POPS-L) remains underexplored, with limited comparative studies to ESWL. This study compared the treatment outcomes of disposable POPS-L tools and ESWL for pancreatic stones. Methods: A retrospective analysis was conducted on 66 patients who had undergone pancreatic stone treatment at three institutions between 2006 and 2022. The treatment outcomes of POPS-L and ESWL were compared. Results: This study included 19 and 47 patients who had undergone POPS-L and ESWL, respectively. In a comparison between POPS-L and ESWL, the stone clearance rates were 78.9% vs. 70.2% (p = 0.55), while the procedure-related complication rates were 21% vs. 6.3% (p = 0.09). The median total session counts were 1 vs. 5 (p < 0.01). The cumulative stone recurrence rates were comparable in both groups. Multivariate analysis revealed no significant factors influencing the stone clearance rates, and the choice between POPS-L and ESWL did not affect the stone clearance rates. Conclusions: POPS-L and ESWL exhibited comparable treatment outcomes in terms of stone clearance, complications, and recurrence rates. Furthermore, POPS-L is advantageous due to the need for fewer sessions to achieve pancreatic stone clearance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

62. Comparison of unilateral and bilateral intraductal plastic stent placement for unresectable malignant hilar biliary obstruction: A propensity score‐matched cohort analysis.

Author

Okuno, Mitsuru, Iwata, Keisuke, Mukai, Tsuyoshi, Iwasa, Yuhei, Uemura, Shinya, Yoshida, Kensaku, Maruta, Akinori, Iwashita, Takuji, Yasuda, Ichiro, and Shimizu, Masahito

Abstract

Background: Although intraductal plastic stent (IS) placement is an effective treatment for unresectable malignant hilar biliary obstruction (UMHBO), the effectiveness of unilateral and bilateral IS drainage remains controversial. This retrospective study investigated the effectiveness of bilateral IS placement for UMHBO using the propensity score matching method. Methods: Patients who underwent transpapillary endoscopic stenting for UMHBO were analyzed for technical and clinical success, adverse events, and time to recurrent biliary obstruction (TRBO). Results: A total of 321 patients were enrolled in the study with 27 patients in each unilateral and bilateral IS group in the propensity score‐based cohort. Technical success was 100%, while clinical success was 93% and 96% in the unilateral and bilateral IS groups, respectively (p = 1.0). Cholecystitis occurred in 4% and 7%, respectively (p = 1.0). The median TRBO was shorter in the unilateral group (129 [5–383] days) than that in the bilateral group (226 [16–563] days) (p =.0281). Bilateral IS placement was an independent long TRBO factor (hazard ratio [HR] 0.46; 95% confidence interval [CI]: 0.21–0.97; p =.041). Conclusions: Unilateral and bilateral IS placement had high technical and clinical success rates in primary stent placement. However, bilateral IS placement showed a longer TRBO. Bilateral IS placement may be a good option for initial UMHBO drainage. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

63. Impact of post‐progression survival in second‐line treatment with molecular target agents for unresectable hepatocellular carcinoma.

Author

Tajiri, Kazuto, Muraishi, Nozomu, Murayama, Aiko, Hayashi, Yuka, and Yasuda, Ichiro

Subjects
DRUG target, PROGRESSION-free survival, OVERALL survival, DATABASES, DISEASE progression, HEPATOCELLULAR carcinoma
Abstract

Aim: Sequential therapies are essential to extend overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC). Several second‐line treatments with molecular target agents have shown survival benefits. However, the significance of post‐progression survival (PPS) in extending OS in patients with HCC given such treatments remains uncertain. Methods: Through a systematic review of the literature in the PubMed database, this study investigated the correlation between PPS and OS and that between progression‐free survival (PFS) and OS in patients with HCC given second‐line treatments. Results: In total, 3935 patients who had received second‐line treatment with regorafenib, ramucirumab, or cabozantinib, which are approved molecular target agents, were identified. In the patients treated with regorafenib, PPS showed a strong correlation with OS (R2 = 0.729, R = 0.854, p < 0.001) whereas PFS showed a weak correlation (R2 = 0.218, R = 0.467, p = 0.021). In the patients treated with ramucirumab, PPS showed a strong correlation with OS (R2 = 0.800, R = 0.894, p = 0.016) whereas PFS showed a negligible correlation (R2 = 0.020, R = 0.140, p = 0.791). In the patients treated with cabozantinib, PPS showed a strong correlation with OS (R2 = 0.856, R = 0.925, p = 0.003) as did PFS (R2 = 0.946, R = 0.973, p < 0.001). Conclusions: PPS plays a more significant role than PFS in extending OS in patients given second‐line treatment for unresectable HCC. Sequential therapies after disease progression in second‐line treatment are essential to acquire good OS. Maintenance of hepatic reserve function and the patient's general condition is essential during systemic treatments for unresectable HCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

64. Comparison of unilateral and bilateral intraductal plastic stent placement for unresectable malignant hilar biliary obstruction: A propensity score‐matched cohort analysis

Author

Okuno, Mitsuru, primary, Iwata, Keisuke, additional, Mukai, Tsuyoshi, additional, Iwasa, Yuhei, additional, Uemura, Shinya, additional, Yoshida, Kensaku, additional, Maruta, Akinori, additional, Iwashita, Takuji, additional, Yasuda, Ichiro, additional, and Shimizu, Masahito, additional

Published
2023
Full Text
View/download PDF

65. Comparison of covered self-expandable metallic stents with 12-mm and 10-mm diameters for unresectable malignant distal biliary obstructions: A prospective randomized trial

Author

Mukai, Tsuyoshi, primary, Iwata, Keisuke, additional, Iwashita, Takuji, additional, Doi, Shinpei, additional, Kawakami, Hiroshi, additional, Okuno, Mitsuru, additional, Maruta, Akinori, additional, Uemura, Shinya, additional, Shimizu, Masahito, additional, and Yasuda, Ichiro, additional

Published
2023
Full Text
View/download PDF

67. Preventive effect of a traditional Japanese Kampo medicine, shakuyakukanzoto, against neurotoxicity of FOLFOX plus bevacizumab used for metastatic colorectal cancer management: A single‐arm phase II study

Author

Takagi, Hiroaki, primary, Kajiura, Shinya, additional, Hosokawa, Ayumu, additional, Horikawa, Naoki, additional, Terada, Itsuro, additional, Hata, Taishi, additional, Kobayashi, Yuka, additional, Tsukioka, Yuji, additional, Yabushita, Kazuhisa, additional, Matsuo, Takashi, additional, Yoshita, Hiroki, additional, Ueda, Akira, additional, Ogawa, Kohei, additional, Ando, Takayuki, additional, Hayashi, Ryuji, additional, and Yasuda, Ichiro, additional

Published
2023
Full Text
View/download PDF

68. Liver metastasis affects progression pattern during immune checkpoint inhibitors monotherapy in gastric cancer

Author

Motoo, Iori, primary, Ando, Takayuki, additional, Hamashima, Takeru, additional, Kajiura, Shinya, additional, Sakumura, Miho, additional, Ueda, Yuko, additional, Murayama, Aiko, additional, Ogawa, Kohei, additional, Tsukada, Kenichiro, additional, Ueda, Akira, additional, Suzuki, Nobuhiro, additional, Nakada, Naokatsu, additional, Nakashima, Koji, additional, Hosokawa, Ayumu, additional, and Yasuda, Ichiro, additional

Published
2023
Full Text
View/download PDF

69. Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma

Author

Tajiri, Kazuto, primary, Tsukada, Kenichiro, additional, Tokimitsu, Yoshiharu, additional, Motofuji, Yuchi, additional, Kawai, Kengo, additional, Muraishi, Nozomu, additional, Murayama, Aiko, additional, Hayashi, Yuka, additional, Shimizu, Yukihiro, additional, and Yasuda, Ichiro, additional

Published
2023
Full Text
View/download PDF

70. ERCP using balloon-assisted endoscope versus EUS-guided treatment for common bile duct stones in Roux-en-Y gastrectomy

Author

Sato, Tatsuya, primary, Nakai, Yousuke, additional, Kogure, Hirofumi, additional, Mitsuyama, Toshiyuki, additional, Shimatani, Masaaki, additional, Uemura, Shinya, additional, Iwashita, Takuji, additional, Tanisaka, Yuki, additional, Ryozawa, Shomei, additional, Tsuchiya, Takayoshi, additional, Itoi, Takao, additional, Kin, Toshifumi, additional, Katanuma, Akio, additional, Kashima, Ken, additional, Irisawa, Atsushi, additional, Kayashima, Atsuto, additional, Iwasaki, Eisuke, additional, Yoshida, Akihiro, additional, Takenaka, Mamoru, additional, Himei, Hitomi, additional, Kato, Hironari, additional, Masuda, Atsuhiro, additional, Shiomi, Hideyuki, additional, Kawakubo, Kazumichi, additional, Kuwatani, Masaki, additional, Otsuka, Takeshi, additional, Matsubara, Saburo, additional, Nishioka, Nobu, additional, Ogura, Takeshi, additional, Tamura, Takaaki, additional, Kitano, Masayuki, additional, Hayashi, Nobuhiko, additional, Yasuda, Ichiro, additional, and Fujishiro, Mitsuhiro, additional

Published
2023
Full Text
View/download PDF

74. 内視鏡的膵石治療

Author

YASUDA, Ichiro, primary, ENTANI, Toshiki, additional, MATSUNO, Jun, additional, HAYASHI, Nobuhiko, additional, and IWATA, Keisuke, additional

Published
2023
Full Text
View/download PDF

77. INVERSE ASSOCIATION OF HOSPITAL VOLUME WITH IN-HOSPITAL MORTALITY RATE OF PATIENTS RECEIVING ENDOSCOPIC ULTRASOUND-GUIDED INTERVENTIONS FOR PANCREATIC FLUID COLLECTIONS

Author

Saito, Tomotaka, primary, Hamada, Tsuyoshi, additional, Michihata, Nobuaki, additional, Iwashita, Takuji, additional, Shiomi, Hideyuki, additional, Takenaka, Mamoru, additional, Matsui, Hiroki, additional, Fushimi, Kiyohide, additional, Fujisawa, Toshio, additional, Matsubara, Saburo, additional, Maruta, Akinori, additional, Iwata, Keisuke, additional, Mukai, Tsuyoshi, additional, Isayama, Hiroyuki, additional, Yasuda, Ichiro, additional, Yasunaga, Hideo, additional, and Nakai, Yousuke, additional

Published
2023
Full Text
View/download PDF

80. International consensus recommendations for difficult biliary access

Author

Liao, Wei-Chih, Angsuwatcharakon, Phonthep, Isayama, Hiroyuki, Dhir, Vinay, Devereaux, Benedict, Khor, Christopher J.L., Ponnudurai, Ryan, Lakhtakia, Sundeep, Lee, Dong-Ki, Ratanachu-ek, Thawee, Yasuda, Ichiro, Dy, Frederick T., Ho, Shiaw-Hooi, Makmun, Dadang, Liang, Huei-Lung, Draganov, Peter V., Rerknimitr, Rungsun, and Wang, Hsiu-Po

Published
2017
Full Text
View/download PDF

84. DPP8 is a novel therapeutic target for multiple myeloma

Author

Sato, Tsutomu, Tatekoshi, Ayumi, Takada, Kohichi, Iyama, Satoshi, Kamihara, Yusuke, Jawaid, Paras, Rehman, Mati Ur, Noguchi, Kyo, Kondo, Takashi, Kajikawa, Sayaka, Arita, Kotaro, Wada, Akinori, Murakami, Jun, Arai, Miho, Yasuda, Ichiro, Dang, Nam H., Hatano, Ryo, Iwao, Noriaki, Ohnuma, Kei, and Morimoto, Chikao

Published
2019
Full Text
View/download PDF

85. Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.

Author

Tajiri, Kazuto, Tsukada, Kenichiro, Tokimitsu, Yoshiharu, Motofuji, Yuchi, Kawai, Kengo, Muraishi, Nozomu, Murayama, Aiko, Hayashi, Yuka, Shimizu, Yukihiro, and Yasuda, Ichiro

Subjects
THERAPEUTIC use of monoclonal antibodies, THERAPEUTIC use of antineoplastic agents, DISEASE progression, RETROSPECTIVE studies, ACQUISITION of data, TREATMENT effectiveness, CANCER patients, SURVIVAL analysis (Biometry), DESCRIPTIVE statistics, MEDICAL records, BEVACIZUMAB, PROGRESSION-free survival, HEPATOCELLULAR carcinoma, OVERALL survival
Abstract

Introduction: Atezolizumab plus bevacizumab (Atez/Bev) is a standard treatment for unresectable hepatocellular carcinoma (HCC) due to its good antitumor and survival prolongation effects. Post-progression survival (PPS) has been reported to be a great contributor in the treatment with tyrosine kinase inhibitors for unresectable HCC. This study aimed to clarify the significance of progression-free survival (PFS) or PPS of Atez/Bev treatment for HCC. Methods: We analyzed the correlations of PFS and PPS with overall survival (OS) in studies of HCC patients treated with Atez/Bev and evaluated the contribution to OS in Atez/Bev treatment with patients at our institutions as clinical practice. Results: Analysis of 18 studies involving 3,752 patients treated with Atez/Bev found that PPS had a stronger correlation with OS (R2 = 0.872, p < 0.001) than did PFS (R2 = 0.605, p = 0.001). Analysis of 80 patients with unresectable HCC treated with Atez/Bev found that presence of antitumor responses during Atez/Bev was the most significant contributor to OS, and post-progression treatment after Atez/Bev also significantly contribute to OS. Conclusion: The presence of antitumor response with tumor shrinkage during Atez/Bev treatment contributes to good OS through its durable response. Atez/Bev treatment could be considered as first-line treatment for unresectable HCC. However, there is a need for optimal biomarkers for good antitumor response. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

89. Comparing endoscopic ultrasound‐guided antegrade treatment and balloon endoscopy‐assisted endoscopic retrograde cholangiopancreatography in the management of bile duct stones in patients with surgically altered anatomy: A retrospective cohort study

Author

Iwashita, Takuji, primary, Iwasa, Yuhei, additional, Senju, Akihiko, additional, Tezuka, Ryuichi, additional, Uemura, Shinya, additional, Okuno, Mitsuru, additional, Iwata, Keisuke, additional, Mukai, Tsuyoshi, additional, Yasuda, Ichiro, additional, and Shimizu, Masahito, additional

Published
2023
Full Text
View/download PDF

90. Time to think prime times for treatment of necrotizing pancreatitis: Pendulum conundrum.

Author

Nakai, Yousuke, Hamada, Tsuyoshi, Saito, Tomotaka, Shiomi, Hideyuki, Maruta, Akinori, Iwashita, Takuji, Iwata, Keisuke, Takenaka, Mamoru, Masuda, Atsuhiro, Matsubara, Saburo, Sato, Tatsuya, Mukai, Tsuyoshi, Yasuda, Ichiro, Isayama, Hiroyuki, Nakano, Ryota, Ota, Shogo, Yoshida, Kensaku, Tezuka, Ryuichi, Akihiko, Senju, and Uemura, Shinya

Subjects
NECROTIZING pancreatitis, PENDULUMS, TREATMENT effectiveness, ENDOSCOPIC ultrasonography, RHINORRHEA
Abstract

Pancreatic fluid collections (PFCs) typically develop as local complications of acute pancreatitis and complicate the clinical course of patients with acute pancreatitis and potentially fatal clinical outcomes. Interventions are required in cases of symptomatic walled‐off necrosis (WON) (matured PFCs with necrosis) and pancreatic pseudocysts (matured PFCs without necrosis). In the management of necrotizing pancreatitis and WON, endoscopic ultrasound‐guided transluminal drainage combined with on‐demand endoscopic necrosectomy (i.e. the step‐up approach) is increasingly used as a less invasive treatment modality compared with a surgical or percutaneous approach. Through the substantial research efforts and development of specific devices and stents (e.g. lumen‐apposing metal stents), endoscopic techniques of PFC management have been standardized to some extent. However, there has been no consensus about timing of carrying out each treatment step; for instance, it is uncertain when direct endoscopic necrosectomy should be initiated and finished and when a plastic or metal stent should be removed following clinical treatment success. Despite emerging evidence for the effectiveness of noninterventional supportive treatment (e.g. antibiotics, nutritional support, irrigation of the cavity), there has been only limited data on the timing of starting and stopping the treatment. Large studies are required to optimize the timing of those treatment options and improve clinical outcomes of patients with PFCs. In this review, we summarize the current available evidence on the indications and timing of interventional and supportive treatment modalities for this patient population and discussed clinical unmet needs that should be addressed in future research. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

91. A novel anti-reflux biliary metal stent with a distal tapered end for distal malignant biliary obstruction: a feasibility study

Author

Doi, Shinpei, additional, Namura, Yuta, additional, Kikuyama, Tomohiro, additional, Saito, Go, additional, Adachi, Takako, additional, Matsumoto, Kotaro, additional, Watanabe, Ayako, additional, Tsunashima, Hiromichi, additional, Katsukura, Nobuhiro, additional, Tsujikawa, Takayuki, additional, and Yasuda, Ichiro, additional

Published
2023
Full Text
View/download PDF

93. Clinical significance of CA125 in unresectable pancreatic cancer treated with first-line chemotherapy.

Author

Motoo, Iori, primary, Ando, Takayuki, additional, Yuki, Satoshi, additional, Ito, Ken, additional, Ueda, Akira, additional, Kito, Yosuke, additional, Sakumura, Miho, additional, Kajiura, Shinya, additional, Matsuno, Jun, additional, Nakamura, Yoshifumi, additional, Inoue, Yuma, additional, Hayashi, Nobuhiko, additional, Hosokawa, Ayumu, additional, Shibuya, Kazuto, additional, Tanaka, Haruyoshi, additional, Fukasawa, Mina, additional, Fujii, Tsutomu, additional, and Yasuda, Ichiro, additional

Published
2023
Full Text
View/download PDF

94. CA125 kinetics as a potential biomarker of prognosis in nivolumab monotherapy for patients with advanced gastric cancer and peritoneal metastasis.

Author

Ando, Takayuki, primary, Yuki, Satoshi, additional, Kito, Yosuke, additional, Ueda, Akira, additional, Motoo, Iori, additional, Ito, Ken, additional, Sakumura, Miho, additional, Ueda, Yuko, additional, Kajiura, Shinya, additional, Nakada, Naokatsu, additional, Nakajima, Koji, additional, Hosokawa, Ayumu, additional, Harada, Kazuaki, additional, Kawamoto, Yasuyuki, additional, Komatsu, Yoshito, additional, and Yasuda, Ichiro, additional

Published
2023
Full Text
View/download PDF

95. CA125 kinetics as a potential biomarker for ascites progression during taxane plus ramucirumab therapy in patients with advanced gastric cancer.

Author

Ueda, Akira, primary, Yuki, Satoshi, additional, Ando, Takayuki, additional, Motoo, Iori, additional, Ito, Ken, additional, Kito, Yosuke, additional, Sakumura, Miho, additional, Ueda, Yuko, additional, Kajiura, Shinya, additional, Nakada, Naokatsu, additional, Nakajima, Koji, additional, Hosokawa, Ayumu, additional, Harada, Kazuaki, additional, Kawamoto, Yasuyuki, additional, Komatsu, Yoshito, additional, and Yasuda, Ichiro, additional

Published
2023
Full Text
View/download PDF

96. Randomized multicenter phase III trial of neoadjuvant gemcitabine + cisplatin + S-1 (GCS) versus surgery first for resectable biliary tract cancer (JCOG1920: NABICAT).

Author

Nara, Satoshi, primary, Ioka, Tatsuya, additional, Ogawa, Gakuto, additional, Kataoka, Tomoko, additional, Sano, Yusuke, additional, Esaki, Minoru, additional, Nagano, Hiroaki, additional, Kudo, Masatoshi, additional, Ikeda, Masafumi, additional, Kanai, Masashi, additional, Yasuda, Ichiro, additional, Yamazaki, Kentaro, additional, Shirakawa, Hirofumi, additional, Kobayashi, Shogo, additional, Ozaka, Masato, additional, Gotohda, Naoto, additional, Hatano, Etsuro, additional, Furuse, Junji, additional, Okusaka, Takuji, additional, and Ueno, Makoto, additional

Published
2023
Full Text
View/download PDF

97. WONDER-01: immediate necrosectomy vs. drainage-oriented step-up approach after endoscopic ultrasound-guided drainage of walled-off necrosis—study protocol for a multicentre randomised controlled trial

Author

Sato, Tatsuya, primary, Saito, Tomotaka, additional, Takenaka, Mamoru, additional, Iwashita, Takuji, additional, Shiomi, Hideyuki, additional, Fujisawa, Toshio, additional, Hayashi, Nobuhiko, additional, Iwata, Keisuke, additional, Maruta, Akinori, additional, Mukai, Tsuyoshi, additional, Masuda, Atsuhiro, additional, Matsubara, Saburo, additional, Hamada, Tsuyoshi, additional, Inoue, Tadahisa, additional, Ohyama, Hiroshi, additional, Kuwatani, Masaki, additional, Kamada, Hideki, additional, Hashimoto, Shinichi, additional, Shiratori, Toshiyasu, additional, Yamada, Reiko, additional, Kogure, Hirofumi, additional, Ogura, Takeshi, additional, Nakahara, Kazunari, additional, Doi, Shinpei, additional, Chinen, Kenji, additional, Isayama, Hiroyuki, additional, Yasuda, Ichiro, additional, and Nakai, Yousuke, additional

Published
2023
Full Text
View/download PDF

99. Impact of COVID‐19 infection and vaccination in pancreatobiliary IgG4‐related disease patients: An international multicenter study

Author

Tang, Raymond S Y, primary, Sattayalertyanyong, Onuma, additional, Kuo, Yu‐Ting, additional, Park, Kenneth H, additional, Anastassiades, Constantinos, additional, Ligresti, Dario, additional, Hayashi, Nobuhiko, additional, Hasan, Aws, additional, Kim, Tae‐Hyeon, additional, Pausawasdi, Nonthalee, additional, Wang, Hsiu‐Po, additional, Lo, Simon K, additional, Ho, Khek‐Yu, additional, Barresi, Luca, additional, Traina, Mario, additional, Yasuda, Ichiro, additional, Savides, Thomas J, additional, Koo, Chieh‐Sian, additional, Chan, Ting Ting, additional, Lam, Thomas Y T, additional, and Sung, Joseph J Y, additional

Published
2023
Full Text
View/download PDF

100. Dose-Related Difference and Involvement of Tyrosine Phosphorylation in Methylmercury-Induced Morphological Change in Cultured Astrocytes Obtained from Rat Cerebral Hemisphere

Author

Adachi, Tatsumi, primary, Shimizu, Hideaki, additional, Kawasumi, Kohei, additional, Suzuki, Yuka, additional, Hayashi, Tomoharu, additional, Tsurusaki, Ryota, additional, Watanabe, Yosuke, additional, Iwasaki, Mitsunori, additional, Yanagisawa, Yasuhide, additional, and Yasuda, Ichiro, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results